Alembic's JV Aleor Dermaceuticals receives USFDA approval for Clobetasol Propionate Spray, 0.05%

Alembic Pharmaceuticals announced that its joint venture Aleor Dermaceuticals (Aleor) has received approval from - the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Clobetasol Propionate Spray, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Clobex Spray, 0.05% of Galderma Laboratories L.P. (Galderma). Clobetasol Propionate Spray, 0.05% is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.

Powered by Capital Market - Live News